Recent developments include the appointment of an interim Chief Financial Officer and the company’s reporting of preliminary 2025 results with revenue growth guidance. Multiple analyst firms have maintained buy recommendations.

• On February 26, 2026, MDxHealth appointed Ron Kalfus as interim Chief Financial Officer [N1][S2].
• In January 2026, the company posted preliminary 2025 results and indicated revenue growth of 26% to 28% for 2026 [N2].
• Several analyst firms including TD Cowen, Lake Street, and BTIG maintained buy recommendations in late 2025 [N3][N4][N5].
• MDxHealth reported a Q2 2025 loss but topped revenue estimates [N6].
• The company announced a CFO transition and appointed Michael Holder as Chair of the Audit Committee in July 2025 [N7].
• MDxHealth reported a Q1 2025 loss but exceeded revenue estimates [N8].

MDxHealth’s suite of clinically validated, non-invasive molecular diagnostic tests offers personalized genomic insights that improve prostate cancer screening, diagnosis, and treatment decisions, potentially reducing unnecessary biopsies and treatments. The company’s recent acquisition of Exosome Diagnostics and integration of the Exo mdx test broaden its product offerings and customer reach. Strong reimbursement coverage by Medicare and commercial payors supports revenue generation. The focused U.S. commercial strategy with a direct sales force and ongoing physician education efforts aim to increase test adoption. Continued investment in research and development, including the development of Monitor mdx for active surveillance, may enhance the company’s product pipeline and market position [S1][N1][N2].

MDxHealth operates in a highly competitive molecular diagnostics market with rapid technological changes and evolving reimbursement landscapes, which may impact adoption and pricing. The company has incurred net losses since inception and faces ongoing capital requirements to fund operations and growth initiatives. Reimbursement uncertainties and potential delays in coverage expansion could constrain revenue growth. Dependence on a limited number of suppliers for certain laboratory materials and equipment presents operational risks. Additionally, the company’s ability to expand its commercial footprint outside the U.S. remains limited, and any failure to increase physician adoption or manage costs could affect financial performance [S1].

MDxHealth’s competitive strengths include a targeted menu of precision diagnostic tests that address significant unmet clinical needs in prostate cancer diagnosis and treatment, supported by strong clinical validation and inclusion in recognized clinical guidelines. The company benefits from a robust reimbursement strategy with Medicare and commercial payors, a direct sales force with established relationships in the urology community, and proprietary technology supported by CAP accredited and CLIA certified laboratory operations. Its acquisition of Exosome Diagnostics expanded its product portfolio and customer base. The company’s management team has industry expertise and a track record of execution, contributing to its commercial channel advantage and ability to expand test adoption. These factors collectively create barriers to entry and support sustainable growth in a competitive molecular diagnostics market [S1].

• Reimbursement Risk: The company’s revenue depends heavily on Medicare and commercial payor coverage and reimbursement policies, which can change and affect test adoption and pricing.
• Competitive Risk: The molecular diagnostics field is highly competitive with rapid technological advances and new product introductions that may challenge MDxHealth’s market position.
• Capital and Liquidity Risk: MDxHealth has a history of net losses and requires ongoing capital to fund operations and growth. Access to financing on acceptable terms is uncertain.
• Operational Risk: Dependence on limited suppliers for key laboratory materials and equipment could disrupt testing services.

• MDxHealth SA is a Belgium-incorporated, commercial-stage precision diagnostics company focused on non-invasive, clinically actionable, and cost-effective urologic solutions, primarily for prostate cancer and urinary tract infections (UTIs).
• The company offers a core menu of molecular diagnostic tests: Confirm mdx, GPS mdx, and Exo mdx, which provide personalized DNA and RNA insights to physicians and patients for prostate cancer screening, diagnosis, and treatment decisions.
• Exo mdx is a non-invasive urine test (no digital rectal exam required) with a 91% negative predictive value for clinically significant prostate cancer, used to help determine the need for biopsy.
• Confirm mdx analyzes biopsy tissue to improve biopsy accuracy with a 96% negative predictive value for clinically significant disease.
• GPS mdx measures gene expression in prostate cancer tissue to predict adverse pathology and risk of metastasis, aiding treatment decisions and identifying patients who may avoid unnecessary interventions.
• Resolve mdx is a urinary tract infection test providing pathogen identification and personalized antibiotic susceptibility within 48 hours, reimbursed by Medicare and private payors.
• The company acquired Exosome Diagnostics, Inc. and its Exo mdx test in September 2025, transitioning customers from Select mdx to Exo mdx.
• More than 7,000 urologists have ordered over 500,000 mdxhealth tests.
• All core tests are recognized in National Comprehensive Cancer Network (NCCN) guidelines and reimbursed by Medicare.
• The company operates a CAP accredited, CLIA certified, and NYSDOH approved molecular laboratory in the United States, with investments focused there.
• MDxHealth has a direct sales force in the United States targeting urology-focused networks, supported by payor and reimbursement, revenue cycle management, and client services teams.
• The company’s strategy includes physician and patient education, expanding the test menu (including development of Monitor mdx for active surveillance), and expanding reimbursement coverage.
• Financial figures for the year ended December 31, 2025, include revenue of $107.9 million, net loss of $33.5 million, and basic and diluted EPS of -$0.67 per share.
• Liquidity as of December 31, 2025, includes cash and cash equivalents of $29.0 million, current assets of $53.4 million, current liabilities of $49.5 million, with a current ratio of 1.08 and cash ratio of 0.59.
• Capital expenditures for 2025 were $1.2 million, primarily for laboratory equipment, IT equipment, and leasehold improvements.
• Research and development expenses for 2025 were $10.4 million, mainly for pipeline product development including labor, reagents, clinical studies, and patent expenses.
• Selling and marketing expenses increased moderately in 2025, reflecting growth in commercial sales team incentives and revenues.
• The company has incurred net losses since inception and has an accumulated deficit of approximately $403 million as of December 31, 2025.
• MDxHealth has raised capital through public offerings and debt financings, with recent gross proceeds of $44.4 million in late 2024 and ongoing sales agreements.
• Management estimates that current cash and anticipated cash flows will be sufficient to meet cash requirements for at least the next 12 months from the 2025 annual report date.
• The company faces risks related to reimbursement coverage, competition in molecular diagnostics, and the need to raise additional capital to support growth and operations.
• Recent management changes include appointment of an interim Chief Financial Officer as of February 26, 2026.